Category Archives: Prevention, Engagement and Care Cascade

Prevalence and determinants of virologic failure among HIV patients on ART in Africa: A systematic review and meta-analysis

2025

Background The Joint United Nations Programme on HIV/AIDS (UNAIDS) has established the 95-95-95 targets, aiming that by 2030, 95% of individuals on ART will achieve viral suppression. While the number...

Global human immunodeficiency virus prevalence and risk behaviors in transmasculine Individuals: A scoping review

2025

PURPOSE: This scoping review sought to synthesize human immunodeficiency virus (HIV) and sexually transmitted infection (STI) prevalence, incidence, risk behaviors, and risk perceptions among transmasculine (TM) individuals globally. METHODS: Eligible...

The prevalence of low-level viraemia and its association with virological failure in people living with HIV: A systematic review and meta-analysis

2024

Low-level viraemia (LLV) following antiretroviral therapy (ART) in people living with HIV (PLWH) has not received sufficient attention. To the determine the prevalence of LLV and its association with virological...

The safety of cabotegravir in pregnancy: A systematic review and meta-analysis

2025

BACKGROUND: HIV remains an important global public health crisis. Antiretroviral treatment has been essential to suppress viral replication, and in at-risk individuals, antiretroviral pre-exposure prophylaxis drugs (PrEP) lower transmission rates....

Deep sequencing reveals underestimated burden of integrase inhibitor resistance mutations in people living with HIV: A global individual patient data meta-analysis

2025

Integrase strand transfer inhibitors (INSTIs) have emerged as cornerstone agents in global antiretroviral therapy, though growing drug resistance presents clinical challenges. Conventional Sanger sequencing may underestimate the burden of low-frequency...

Effect of same-day HIV treatment initiation (SDI) on 1-year outcomes in low- and middle-income countries: Systematic review and meta-analysis of randomised trials

2025

Introduction Same-day initiation (SDI) of antiretroviral therapy is recommended for people presenting with HIV who have no contraindications. We reviewed the evidence on SDI interventions in low- and middle-income countries...

Efficacy of raltegravir in achieving virological suppression at delivery in HIV-positive pregnant women: A systematic review and meta-analysis

2025

Background The world’s first HIV integrase inhibitor, raltegravir (RAL), has been widely used for the treatment of HIV infection over the past 15 years, and continues benefiting people living with...

The prevalence of adverse drug reactions to antiretroviral therapy and associated factors among pediatric patients living with HIV in sub-Saharan African countries: A systematic review and meta-analysis

2025

Introduction The greatest burden of HIV infection is in sub-Saharan African countries. The burden of treatment failure among children living with HIV remains significantly high due to delayed diagnosis and...

Long-acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re-suppression outcomes in virally suppressed individuals living with HIV

2025

Introduction Randomized controlled trial evidence suggests that long‐acting injectable (LA‐I) cabotegravir and rilpivirine (CAB+RPV) has similar virological failure (VF) rates to daily oral therapy, but clinical practice evidence is lacking....

Barriers to and facilitators of heterosexual men’s engagement with the PrEP care continuum in Sub-Saharan Africa: A scoping review

2025

The HIV epidemic in sub-Saharan Africa (SSA) continues to spread primarily through heterosexual contact, and in many countries, heterosexual men continue to exhibit a high HIV incidence with resultant morbidity...

Dolutegravir + lamivudine effectiveness and tolerability in real-world cohorts with HIV-1 across Asia and South America: A systematic literature review

2025

Background: Dolutegravir (DTG) + lamivudine (3TC) has demonstrated efficacy and safety in phase 3 clinical trials; however, most published data are from people with HIV-1 in North America and Europe. Methods: To...

Gut microbiota of sub-Saharan Africa infants exposed to antiretroviral therapy: Scoping review

2025

Background Antiretroviral (ARV) exposure influences the early-life gut microbiota in regions with high human immunodeficiency virus (HIV) burdens. Understanding how ARV drugs affect the infant gut microbiota is important for...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!